Akebia Therapeutics (NASDAQ: AKBA) net income
Akebia Therapeutics reported a net loss of $5.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $69.4m. Earnings per share were −$0.02.
Fiscal 2025 is the highest of the 10 fiscal years on record for Akebia Therapeutics. It reported a loss in 10 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$5.3m | — | −2.3% | −$0.02 |
| 2024 | −$69.4m | — | −43.3% | −$0.33 |
| 2023 | −$51.9m | — | −26.7% | −$0.28 |
| 2022 | −$94.2m | — | −32.2% | −$0.51 |
| 2021 | −$282.8m | — | −132.4% | −$1.70 |
| 2020 | −$384.8m | — | −130.6% | −$2.77 |
| 2019 | −$279.7m | — | −83.5% | −$2.36 |
| 2018 | −$143.6m | — | −69.1% | — |
| 2017 | −$73.7m | — | −40.7% | — |
| 2016 | −$135.7m | — | −8,843.5% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Akebia Therapeutics net income compared with its sector
By net income for its latest fiscal year, Akebia Therapeutics ranks 183rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Akebia Therapeutics, −2.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 181st | ETON Pharmaceuticals | −$4.6m | −5.8% |
| 182nd | Harrow | −$5.1m | −1.9% |
| 183rd | Akebia Therapeutics | −$5.3m | −2.3% |
| 184th | Assembly Biosciences | −$6.1m | −8.5% |
| 185th | Protalix Biotherapeutics | −$6.6m | −12.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Akebia Therapeutics
- How much did Akebia Therapeutics earn in fiscal 2025?
- Akebia Therapeutics reported a net loss of $5.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $69.4m.
- What are the earnings per share of Akebia Therapeutics?
- They were −$0.02 in fiscal 2025, compared with −$0.33 in fiscal 2024.
- Where does Akebia Therapeutics rank in its sector by net income?
- It ranks 183rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Akebia Therapeutics come from?
- From the annual report (Form 10-K) that Akebia Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Akebia Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Akebia Therapeutics: the Akebia Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.